Corrigendum: Salvinorin A, a kappa-opioid receptor agonist hallucinogen: pharmacology and potential template for novel pharmacotherapeutic agents in neuropsychiatric disorders.
Frontiers in pharmacology – January 01, 2015
Source: PubMed
Summary
A unique compound from *Salvia divinorum*, salvinorin A, shows promise beyond its hallucinogenic effects. Researchers explored its pharmacology, specifically its interaction with the kappa-opioid receptor, typically activated by natural dynorphins. The hypothesis was that salvinorin A could be a template for new treatments. Findings suggest its unique action might offer therapeutic avenues for conditions like depression and addiction, by modulating this receptor system in novel ways. This opens doors for developing agents with fewer side effects.
Abstract
[This corrects the article on p. 190 in vol. 6, PMID: 26441647.].